• Explore /
  • Poster
  • / Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.

Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.

Abstract Poster

Authors

null

Tomás Pascual

SOLTI Cancer Research Group, Barcelona, Spain. Medical Oncology Department, Hospital Clínic de Barcelona, Barcelona, Spain

Tomás Pascual , Daniel G. Stover , Astrid Thuerigen , Rodrigo Sanchez-Bayona , Charles M. Perou , Eva M Ciruelos , Ana Casas , Patricia Spears , Estelle Roux , Fei Su , Huilin Hu , Yen-Shen Lu , Sara M. Tolaney , Ann H. Partridge , Guillermo Villacampa , Juan Manuel Ferrero-Cafiero , Lisa A. Carey , Aleix Prat

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT05207709

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS1125)

DOI

10.1200/JCO.2023.41.16_suppl.TPS1125

Abstract #

TPS1125

Poster Bd #

339a

Abstract Disclosures

Similar Posters

First Author: Michelino DeLaurentiis

First Author: Yen-Shen Lu

First Author: Sara A. Hurvitz

First Author: Mario Campone